From: Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
Baseline period
Treatment period
p*
sTNF-R I (ng/ml)
1.4 [0.05]
1.4 [0.09]
n.s.
sTNF-R II (ng/ml)
3.3 [0.3]
3.4 [0.2]
IL-1 ra (pg/ml)
262.9 [43.2]
246.4 [37.8]
sVCAM-1 (ng/ml)
430.7 [28.9]
484.6 [52.6]